X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1351) 1351
Book Review (309) 309
Publication (103) 103
Book Chapter (17) 17
Conference Proceeding (9) 9
Dissertation (6) 6
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1029) 1029
clodronate (887) 887
humans (724) 724
female (487) 487
bisphosphonates (460) 460
oncology (413) 413
animals (381) 381
male (366) 366
diphosphonates - therapeutic use (343) 343
bone neoplasms - secondary (291) 291
zoledronic acid (281) 281
double-blind (250) 250
pamidronate (238) 238
middle aged (234) 234
aged (196) 196
breast cancer (185) 185
mice (185) 185
bone metastases (184) 184
bone density conservation agents - therapeutic use (179) 179
bisphosphonate (178) 178
bone neoplasms - drug therapy (177) 177
clodronic acid - therapeutic use (177) 177
osteoporosis (177) 177
breast-cancer (170) 170
oral clodronate (168) 168
macrophages (166) 166
rats (160) 160
clodronic acid - administration & dosage (158) 158
pharmacology & pharmacy (156) 156
breast neoplasms - pathology (154) 154
breast neoplasms - drug therapy (151) 151
endocrinology & metabolism (140) 140
clodronic acid - pharmacology (138) 138
adult (136) 136
alendronate (136) 136
in-vitro (136) 136
diphosphonates - pharmacology (128) 128
cancer (124) 124
placebo-controlled trial (123) 123
liposomes (122) 122
adjuvant clodronate treatment (119) 119
multiple-myeloma (115) 115
skeletal complications (115) 115
diphosphonates - administration & dosage (114) 114
treatment outcome (112) 112
cells (108) 108
diphosphonates (103) 103
metastasis (103) 103
bone (99) 99
postmenopausal women (94) 94
care and treatment (89) 89
bone density - drug effects (88) 88
imidazoles - therapeutic use (88) 88
apoptosis (85) 85
prevention (85) 85
antineoplastic agents - therapeutic use (82) 82
inflammation (82) 82
randomized controlled-trial (80) 80
therapy (79) 79
controlled trial (78) 78
pain (78) 78
aged, 80 and over (77) 77
hypercalcemia (76) 76
diphosphonates - adverse effects (75) 75
metastases (75) 75
prostate cancer (75) 75
bone neoplasms - prevention & control (74) 74
drug therapy (74) 74
prostatic neoplasms - pathology (73) 73
follow-up (71) 71
research (71) 71
women (71) 71
abridged index medicus (69) 69
analysis (69) 69
chemotherapy (68) 68
disease (68) 68
administration, oral (67) 67
bone density conservation agents - administration & dosage (67) 67
macrophages - drug effects (67) 67
medicine & public health (67) 67
resorption (67) 67
ibandronate (66) 66
health aspects (65) 65
medicine, general & internal (65) 65
survival (65) 65
disease models, animal (63) 63
double-blind method (63) 63
bone density conservation agents - pharmacology (62) 62
hematology, oncology and palliative medicine (62) 62
etidronate (60) 60
mice, inbred c57bl (60) 60
pain - drug therapy (60) 60
bones (59) 59
chemotherapy, adjuvant (59) 59
clinical trials as topic (59) 59
phosphonates (59) 59
urology & nephrology (59) 59
clodronic acid (58) 58
risk factors (58) 58
bone-mineral density (57) 57
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1299) 1299
German (27) 27
French (20) 20
Spanish (10) 10
Czech (7) 7
Japanese (4) 4
Chinese (2) 2
Italian (2) 2
Korean (2) 2
Russian (2) 2
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 6, pp. 739 - 750
Bisphosphonates (BPs), with a non-hydrolysable P-C-P structure, are cytotoxic analogues of pyrophosphate, bind strongly to bone, are taken into osteoclasts... 
Journal Article
EUROPEAN UROLOGY, ISSN 0302-2838, 06/2015, Volume 67, Issue 6, pp. 1028 - 1038
Background: Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for... 
Control arm cohort | MITOXANTRONE | Time to progression | OPEN-LABEL | Prospective data | Survival | Prognostic factors | ANDROGEN-DEPRIVATION THERAPY | ZOLEDRONIC ACID | PREDNISONE | MEN | UROLOGY & NEPHROLOGY | Hormone-naive | Metastatic | ORAL SODIUM CLODRONATE | Prostate cancer | Natural history | ABIRATERONE | ENZALUTAMIDE
Journal Article
by Coleman, R and Powles, T and Paterson, A and Gnant, M and Anderson, S and Diel, I and Gralow, J and von Minckwitz, G and Moebus, V and Bergh, J and Pritchard, K. I and Bliss, J and Cameron, D and Evans, V and Pan, H and Peto, R and Bradley, R and Gray, R and Pritchard, K and Albain, K and Arriagada, R and Barlow, W and Bergsten-Nordström, E and Boccardo, F and Buyse, M and Clarke, M and Coates, A and Correa, C and Costantino, J and Cuzick, J and Davidson, N and Davies, C and Di Leo, A and Dowsett, M and Ewertz, M and Forbes, J and Gelber, R and Geyer, C and Gianni, L and Goldhirsch, A and Hayes, D and Hill, C and Ingle, J and Janni, W and MacKinnon, E and Martín, M and McGale, P and Norton, L and Ohashi, Y and Paik, S and Perez, E and Piccart, M and Pierce, L and Raina, V and Ravdin, P and Robertson, J and Rutgers, E and Sparano, J and Swain, S and Taylor, C and Viale, G and Wang, X and Whelan, T and Wilcken, N and Winer, E and Wolmark, N and Wood, W and Abe, O and Abe, R and Enomoto, K and Kikuchi, K and Koyama, H and Masuda, H and Nomura, Y and Sakai, K and Sugimachi, K and Toi, M and Tominaga, T and Uchino, J and Yoshida, M and Haybittle, J. L and Leonard, C. F and Calais, G and Garaud, P and Collett, V and Delmestri, A and Sayer, J and Harvey, V. J and Holdaway, I. M and Kay, R. G and Mason, B. H and Forbes, J. F and Bartsch, R and Dubsky, P and Fesl, C and Fohler, H and Greil, R and Jakesz, R and Lang, A and Luschin-Ebengreuth, G and ... and Novartis Pharmaceuticals and Early Breast Canc Trialists and Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10001, pp. 1353 - 1361
Journal Article
Nuclear Medicine and Biology, ISSN 0969-8051, 05/2008, Volume 35, Issue 4, pp. 501 - 514
Introduction: Nanoparticles (NP) have potential as carriers for drugs and radioisotopes. Quantitative measures of NP biodistribution in vivo are needed to... 
Nanoparticles | Antibody targeted | Clodronate | SPECT/CT
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 5, pp. 770 - 777
Bisphosphonates (BPs) are typical anti-bone-resorptive drugs, with nitrogen-containing BPs (N-BPs) being stronger than non-nitrogen-containing BPs (non-N-BPs).... 
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 9, pp. 2651 - 2657
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2011, Volume 365, Issue 15, pp. 1396 - 1405
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 631 - 641
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 23, pp. 2719 - 2720
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 997 - 1006
Journal Article